Evidence map›Paper›PMID 21997247›Full record

ArticleCancer prevention research (Philadelphia, Pa.)2012

Hops (Humulus lupulus) inhibits oxidative estrogen metabolism and estrogen-induced malignant transformation in human mammary epithelial cells (MCF-10A).

L P Hemachandra, P Madhubhani, R Chandrasena, P Esala, Shao-Nong Chen, Matthew Main, David C Lankin, Robert A Scism, Birgit M Dietz, Guido F Pauli and 2 more

Open access · greenAbstract read
In one paragraph

Article in Cancer prevention research (Philadelphia, Pa.), 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
6.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 46 citations in OpenAlex.

  1. Pharmaceuticals (Basel, Switzerland) · 2025
    Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

L P HemachandraDepartment of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, University of Illinois at Chicago, 833 S. Wood Street, Chicago, IL 60612-7231, USA.
P Madhubhani
R Chandrasena
P Esala
Shao-Nong Chen
Matthew Main
David C Lankin
Robert A Scism
Birgit M Dietz
Guido F Pauli
Gregory R J Thatcher
Judy L Bolton
University of Illinois Chicago · US

Funding

Van Breemen: Project 3; Botanical Dietary Supplements - Metabolism and Safety in Women (Van Breemen)P50AT000155 · NCCIH · UNIVERSITY OF ILLINOIS AT CHICAGO · PI PAULI, GUIDO F · 1999 to 2019
$30.4M
Role of electrophilic/redox active quinoids in estrogen carcinogenesisR01CA130037 · NCI · UNIVERSITY OF ILLINOIS AT CHICAGO · PI BOLTON, JUDY L · 2007 to 2011
$1.4M
NCCIH NIH HHS P50 AT000155NCCIH NIH HHS P50 AT00155NCI NIH HHS CA130037NCI NIH HHS R01 CA130037
6 · The paper itself

Abstract

Long-term exposure to estrogens including those in traditional hormone replacement therapy (HRT) increases the risk of developing hormone-dependent cancers. As a result, women are turning to over-the-counter (OTC) botanical dietary supplements, such as black cohosh (Cimicifuga racemosa) and hops (Humulus lupulus), as natural alternatives to HRT. The two major mechanisms which likely contribute to estrogen and/or HRT cancer risk are: the estrogen receptor-mediated hormonal pathway; and the chemical carcinogenesis pathway involving formation of estrogen quinones that damage DNA and proteins, hence initiating and promoting carcinogenesis. Because, OTC botanical HRT alternatives are in widespread use, they may have the potential for chemopreventive effects on estrogen carcinogenic pathways in vivo. Therefore, the effect of OTC botanicals on estrogen-induced malignant transformation of MCF-10A cells was studied. Cytochrome P450 catalyzed hydroxylation of estradiol at the 4-position leads to an o-quinone believed to act as the proximal carcinogen. Liquid chromatography/tandem mass spectrometry analysis of estradiol metabolites showed that 4-hydroxylation was inhibited by hops, whereas black cohosh was without effect. Estrogen-induced expression of CYP450 1B1 and CYP450 1A1 was attenuated by the hops extract. Two phenolic constituents of hops (xanthohumol, XH; 8-prenylnaringenin, 8-PN) were tested: 8-PN was a potent inhibitor, whereas XH had no effect. Finally, estrogen-induced malignant transformation of MCF-10A cells was observed to be significantly inhibited by hops (5 μg/mL) and 8-PN (50 nmol/L). These data suggest that hops extracts possess cancer chemopreventive activity through attenuation of estrogen metabolism mediated by 8-PN.

Indexed as

Breast NeoplasmsCell Line, TumorCell Transformation, NeoplasticChromatography, LiquidCimicifugaEstradiolEstrogensFemaleHumansHumulusMass SpectrometryModels, ChemicalOxidative StressPlant ExtractsReceptors, EstrogenEstradiolEstrogensPlant ExtractsReceptors, Estrogen

Identifiers

PMID21997247
PMCPMC3252489
OpenAlexW2110654720

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.